Keytruda Approval Boosts Merck But Doesn't Alter Core Thesis

What happened

Merck received a new FDA approval for its cancer drug Keytruda, driving analyst activity and putting the stock in focus today. The approval, likely for the subcutaneous formulation, strengthens Keytruda's commercial position and may delay biosimilar erosion by improving patient convenience. However, this does not change the fundamental overhang: Keytruda still faces a two-step decline from IRA pricing in 2029 and biosimilar entry starting December 2028. Meanwhile, the Gardasil China shipment pause remains unresolved, and management's ~$2.5B 2026 headwind from generics and IRA caps the near-term earnings bridge. The stock's upside remains contingent on scaling new launches and resolving Gardasil, not on line extensions for the existing blockbuster.

Implication

Investors should view today's approval as a modest positive that reinforces Keytruda's near- to medium-term revenue stability, but it does not address the core investment thesis: Merck's valuation depends on replacing ~49% of sales from Keytruda by 2029, not on extending its life. The Gardasil China situation and the quantified $2.5B headwind in 2026 remain unresolved, and the stock at 16.2x P/E already prices in a stable transition. Until management can demonstrate that new launches (Winrevair, Capvaxive) or a China restart offset the erosion, the risk/reward is unattractive. The WAIT rating remains, with attractive entry near $105 if headwinds worsen, and a trim above $135 if the growth narrative gains traction without proof.

Thesis delta

No material shift. The FDA approval for subcutaneous Keytruda is a known and expected catalyst that modestly improves the moat defense but does not change the LOE timeline or the Gardasil overhang. The core thesis remains that Merck's 2026-2027 earnings are constrained by a ~$2.5B headwind and China vaccine uncertainty, and the market needs evidence of post-Keytruda diversification before re-rating. This approval does not alter the 6-12 month wait-and-see stance.